All News

The AUA and the American Association of Clinical Urologists have lost no time in pressing Congress for a better solution on Medicare physician reimbursement following passage of legislation to delay a 27% cut in payments for 10 months.

New data showing an increasing incidence of pediatric stone disease is stimulating more research to further describe and understand this troubling phenomenon.

Injectable long-acting testosterone undecanoate (Aveed) over 9 to 12 months is well tolerated by hypogonadal men, especially in regard to prostate safety and response to concomitant phosphodiesterase type-5 inhibitor therapy.

Results of a survey of pediatricians' practice patterns for children with vesicoureteral reflux (VUR) are worrisome in showing these primary care practitioners are retaining their patients longer before referring them to a specialist.

Radiologically proven VUR was present in 11 mothers and seven fathers as well as in 36 second-degree relatives (aunts, uncles, grandparents) and 73 third-degree relatives (65 first cousins and eight great-aunts, -uncles or -grandparents) of 259 VUR patients in an Irish study.

Results of a retrospective study investigating risk factors for the development of renal parenchymal damage in young children with primary high-grade vesicoureteral reflux (VUR) underscore the importance of early detection and treatment to prevent renal damage or its progression from ongoing VUR.

Use of Dx/HA (Deflux) for the treatment of vesicoureteral reflux (VUR) in children increased rapidly after it gained FDA approval. Despite high rates of utilization and positive early findings, more recent reports are raising questions about long-term outcomes and prompting further research.

Urologists share when they offered surveillance, what protocol they used, and how patients responded to this alternative to immediate treatment for low-risk prostate cancer.

Downgrading of high-grade vesicoureteral reflux (VUR) after endoscopic treatment performed because of breakthrough urinary tract infections results in cessation of febrile UTIs and, often, spontaneous VUR resolution as well.

Without a properly structured estate plan, your heirs may be paying unnecessary estate taxes and probate fees that in many cases can be dramatically reduced or even eliminated.

David Klumpp, PhD, and David T. Uehling, MD, explain the challenges inherent in developing a vaccine for UTI and discuss the status of current research.

A long-term retrospective follow-up of Peyronie's disease patients who have undergone surgery for the condition reveals a rise in curvature recurrence as well as increased postoperative erectile dysfunction.

Knowing current urologist salaries at a hospital or deciding how much to pay a new urologist joining a group practice can be difficult whether you're the applicant or the hiring physician. Several different compensation models exist, each with their own benefits and drawbacks.

Correcting even one or two inefficiencies around your office can allow you to take back time-and money.

The government has contracted with a number of different companies (eg, recovery audit contractors, zone program integrity contractors, and Medicare contractors) to look at all Medicare payments and try to detect billing patterns that are outside the norm.

Urologists' reports of stones in pediatric patients varies by region.

Ever get paid by a pharmaceutical company for participating in research or making a speech? Has a drug rep ever bought you lunch or paid for a round of golf? Those practices could soon be a thing of the past.

To date, we have performed zero-ischemia RPN and LPN in more than 100 patients, including those with all types of challenging tumors. As a result of our growing experience, we now offer zero-ischemia RPN and LPN to virtually all comers, regardless of tumor location or renovascular anatomy.

Hypocitraturia is the leading metabolic risk factor in children with stone disease, and the majority of a study's cohort had an identifiable metabolic cause for their urolithiasis.

When legislative and regulatory initiatives pit one physician group against another, organizations such as the AMA or various state medical societies recognize they cannot win if they get involved in these battles.

An FDA advisory panel recommended against using the RANK ligand inhibitor denosumab (XGEVA) to delay or prevent the spread of castration-resistant prostate cancer in patients at high risk for bone metastases.

The Mount Sinai Hospital, New York, and Integrated Medical Professionals, PLLC (IMP)-a multispecialty practice that includes Advanced Urology Centers of New York and Advanced Radiation Centers of New York-have formed a partnership to provide easier access to screening, assessment, and treatment for complex urologic conditions, as well as improved access to radiation oncology services.

The National Quality Forum recently endorsed two outcomes-based measures from the American College of Surgeons that are pertinent to urology: surgical site infection and urinary tract infection.

Both the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) and alpha-blocker tamsulosin (Flomax) appear to significantly improve scores on the International Prostate Symptom Score (IPSS) compared with placebo in men with signs and symptoms suggestive of BPH.

The FDA has approved Gen-Probe's Progensa PCA3 (Prostate Cancer gene 3) assay to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.

Tracking PSA levels over time offers a more accurate assessment of the risk of life-threatening prostate cancer, and novel PSA velocity risk count testing associated with fluctuations in PSA levels may provide a more effective way to screen for clinically significant prostate cancer, a recent multicenter study concludes.

Give us your opinion on our latest poll, and see what your colleagues are saying. You can see the results of our previous surveys here as well.